Belinostat: clinical applications in solid tumors and lymphoma

Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines

(2017) Marielle Dejligbjerg et al.   Cancer Biomarkers

Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC)

(2017) N. J. Finkler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms

(2017) O. Odenike et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract B238: A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma

(2012) S. Nallapareddy et al.   MOLECULAR CANCER THERAPEUTICS

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Medicinal Chemistry of Sirtuin Inhibitors

(2011) L. Chen   CURRENT MEDICINAL CHEMISTRY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis

(2010) T. A. White et al.   BLOOD

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

(2010) U Lassen et al.   BRITISH JOURNAL OF CANCER

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

(2010) N. L. Steele et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

(2010) Young-Soon Na et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma

(2010) L. Paoluzzi et al.   CLINICAL CANCER RESEARCH

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

(2010) Helen J. Mackay et al.   EUROPEAN JOURNAL OF CANCER

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

(2010) Jiahuai Tan et al.   Journal of Hematology & Oncology

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials

(2010) Paul K. Paik et al.   Journal of Thoracic Oncology

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts

(2009) Anne Monks et al.   ANTI-CANCER DRUGS

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Biomarkers for predicting clinical responses to HDAC inhibitors

(2009) Lindsay Stimson et al.   CANCER LETTERS

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

(2009) Lena Marquard et al.   HISTOPATHOLOGY

The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

(2009) Brigette B.Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

Hunting and Trapping the Vascular Endothelial Growth Factor

(2009) Afshin Dowlati   JOURNAL OF CLINICAL ONCOLOGY

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

(2008) Nagma Khan et al.   BIOCHEMICAL JOURNAL

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

(2008) W Weichert et al.   BRITISH JOURNAL OF CANCER

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

(2008) W. Weichert et al.   CLINICAL CANCER RESEARCH

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

419 POSTER A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced solid tumours

(2008) M. Sorensen et al.   EJC SUPPLEMENTS

420 POSTER A phase I clinical trial of belinostat (PXD101) in combination with doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS)

(2008) A.T. Brunetto et al.   EJC SUPPLEMENTS

213 POSTER Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder

(2008) J. Barriuso et al.   EJC SUPPLEMENTS

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY